Login / Signup

InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis.

Lindsay FlintAaron KorkegianTanya Parish
Published in: PloS one (2020)
We previously identified a diazaborine series with potential for development as a new tuberculosis drug. This series has activity in vitro and in vivo and targets cell wall biosynthesis via inhibition of InhA. The overall aim of this study was to determine whether InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis. We tested the ability of two molecules of the diazaborine series to kill non-replicating M. tuberculosis in the nutrient starvation model; both molecules were bactericidal, reducing viability by >3 logs in 21 days. Activity showed similar kill rates to other InhA inhibitors (isoniazid and NITD-916). We conclude that inhibition of InhA is bactericidal against nutrient-starved non-replicating M. tuberculosis.
Keyphrases
  • mycobacterium tuberculosis
  • pulmonary tuberculosis
  • cell wall
  • emergency department
  • climate change
  • hiv aids
  • human immunodeficiency virus
  • electronic health record
  • antiretroviral therapy